MarketCapExport financials
Puma Biotechnology (PBYI)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Puma Biotechnology Balance Sheet 2025-2010 | PBYI
Brief balance sheet overview of Puma Biotechnology
Balance sheet changes are traced across five available annual reports between 2021 and 2025.
Assets shifted from $226.6 million to $216.3 million, leaving five-period growth close to stagnation.
Liabilities increased less than assets, posting -62.5% versus -4.5%. That relationship usually strengthens the balance sheet.
The equity-to-assets ratio is 60.3%, compared with -1.1% five periods ago. The balance sheet has a substantial internal cushion.
Cash accounts for 13.7% of assets versus 27.9% initially. The change indicates the degree of financial flexibility.
The balance sheet includes a negative accumulated result of -$1.3 billion. It should be assessed alongside historical profits and capital distributions.
Overall assessment
Puma Biotechnology's balance sheet is broadly resilient, though selected areas require monitoring. The balance between assets, equity and liabilities remains the key issue.
Annual Balance Sheet Puma Biotechnology
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | -42 M | -14.1 M | 26.2 M | 37.5 M | 1.83 M | 86.5 M | 100 M | -33.2 M | -194 M | -31.6 M | -38.5 M | -43 M | -137 M | -53.4 M | - |
Long Term Debt |
- | 21.7 M | 65.7 M | 98.3 M | 97.1 M | 84 M | 95 M | 152 M | 48.5 M | - | - | - | - | - | - | - |
Long Term Debt Current |
1.31 M | 5.54 M | 4.8 M | 4.14 M | 3.57 M | 3.09 M | 2.62 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 127 M | 158 M | 53.9 M | 5.5 M | 1.39 M | 1.27 M | 1.12 M | 1.09 M | 439 K | - |
Total Current Liabilities |
81.3 M | 96.1 M | 99.4 M | 77.5 M | 110 M | 114 M | 90.8 M | 67.1 M | 58.3 M | 37.5 M | 32.4 M | 44.4 M | 19.3 M | 21.7 M | 586 K | - |
Total Liabilities |
86 M | 121 M | 177 M | 200 M | 229 M | 250 M | 217 M | 225 M | 112 M | 43 M | 33.8 M | 45.7 M | 20.4 M | 22.8 M | 1.03 M | - |
Retained Earnings |
-1.28 B | -1.31 B | -1.35 B | -1.37 B | -1.37 B | -1.34 B | -1.28 B | -1.2 B | -1.09 B | -797 M | -520 M | -281 M | -139 M | -84.6 M | -10.2 M | - |
Total Assets |
216 M | 213 M | 231 M | 222 M | 227 M | 244 M | 235 M | 259 M | 166 M | 253 M | 240 M | 163 M | 104 M | 152 M | 55.4 M | - |
Cash and Cash Equivalents |
29.6 M | 69.2 M | 84.6 M | 76.2 M | 63.1 M | 85.3 M | 60 M | 108 M | 81.7 M | 194 M | 31.6 M | 38.5 M | 43 M | 137 M | 53.4 M | - |
Book Value |
130 M | 92.1 M | 53.4 M | 21.6 M | -2.45 M | -5.95 M | 17.5 M | 34.3 M | 53.3 M | 210 M | 206 M | 117 M | 84 M | 129 M | 54.4 M | - |
Total Shareholders Equity |
130 M | 92.1 M | 53.4 M | 21.6 M | -2.45 M | -5.95 M | 17.5 M | 34.3 M | 53.3 M | 210 M | 206 M | 117 M | 84 M | 129 M | 54.4 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Puma Biotechnology
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | 10.9 M | 10.6 M | 21.7 M | 32.7 M | 43.7 M | 54.7 M | 65.7 M | 76.6 M | 87.6 M | 98.6 M | 98.3 M | 98 M | - | 97.4 M | 97.1 M | 96.8 M | 68.7 M | 76.3 M | 84 M | 84 M | 84 M | 84 M | 95 M | 95 M | 93.4 M | 95 M | 152 M | 152 M | 152 M | 152 M | 48.5 M | 48.5 M | 48.5 M | 48.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
54.2 M | 64.3 M | 87.6 M | 90.2 M | 99.1 M | 121 M | 150 M | 156 M | 163 M | 177 M | 165 M | 170 M | 170 M | 200 M | 177 M | - | 194 M | 229 M | 237 M | 231 M | 242 M | 250 M | 250 M | 250 M | 250 M | 217 M | 217 M | 217 M | 217 M | 225 M | 225 M | 225 M | 225 M | 112 M | 112 M | 112 M | 112 M | 43 M | 43 M | 43 M | 43 M | 33.8 M | 33.8 M | 33.8 M | 33.8 M | 45.7 M | 45.7 M | 45.7 M | 45.7 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 22.8 M | 22.8 M | 22.8 M | 22.8 M | 1.03 M | 1.03 M | 1.03 M | 1.03 M |
Retained Earnings |
-1.28 B | -1.29 B | -1.3 B | -1.31 B | -1.31 B | -1.31 B | -1.33 B | -1.35 B | -1.35 B | -1.35 B | -1.36 B | -1.36 B | -1.37 B | -1.37 B | -1.36 B | - | -1.37 B | -1.37 B | -1.37 B | -1.33 B | -1.32 B | -1.34 B | -1.34 B | -1.34 B | -1.34 B | -1.28 B | -1.28 B | -1.28 B | -1.28 B | -1.2 B | -1.2 B | -1.2 B | -1.2 B | -1.09 B | -1.09 B | -1.09 B | -1.09 B | -797 M | -797 M | -797 M | -797 M | -520 M | -520 M | -520 M | -520 M | -281 M | -281 M | -281 M | -281 M | -139 M | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
193 M | 193 M | 203 M | 195 M | 196 M | 213 M | 221 M | 205 M | 214 M | 231 M | 204 M | 200 M | 196 M | 222 M | 199 M | - | 201 M | 227 M | 226 M | 260 M | 259 M | 244 M | 244 M | 244 M | 244 M | 235 M | 235 M | 235 M | 235 M | 259 M | 259 M | 259 M | 259 M | 166 M | 166 M | 166 M | 166 M | 253 M | 253 M | 253 M | 253 M | 240 M | 240 M | 240 M | 240 M | 163 M | 163 M | 163 M | 163 M | 104 M | 104 M | 104 M | 104 M | 152 M | 152 M | 152 M | 152 M | 55.4 M | 55.4 M | 55.4 M | 55.4 M |
Cash and Cash Equivalents |
36.5 M | 36.2 M | 53.5 M | 54.7 M | 63 M | 69.2 M | 67.3 M | 67.1 M | 76.8 M | 84.6 M | 81.8 M | 60 M | 61.4 M | 76.2 M | 78 M | - | 63.9 M | 63.1 M | 63.9 M | 89.8 M | 95.7 M | 85.3 M | 85.3 M | 85.3 M | 85.3 M | 60 M | 60 M | 60 M | 60 M | 108 M | 108 M | 108 M | 108 M | 81.7 M | 81.7 M | 81.7 M | 81.7 M | 194 M | 194 M | 194 M | 194 M | 31.6 M | 31.6 M | 31.6 M | 31.6 M | 38.5 M | 38.5 M | 38.5 M | 38.5 M | 43 M | 43 M | 43 M | 43 M | 137 M | 137 M | 137 M | 137 M | 53.4 M | 53.4 M | 53.4 M | 53.4 M |
Book Value |
139 M | 128 M | 115 M | 105 M | 97.1 M | 92.1 M | 71.1 M | 48.5 M | 51 M | 53.4 M | 38.7 M | 30.4 M | 25.8 M | 21.6 M | 22.2 M | - | 7.14 M | -2.45 M | -10.9 M | 29.5 M | 16.4 M | -5.95 M | -5.95 M | -5.95 M | -5.95 M | 17.5 M | 17.5 M | 17.5 M | 17.5 M | 34.3 M | 34.3 M | 34.3 M | 34.3 M | 53.3 M | 53.3 M | 53.3 M | 53.3 M | 210 M | 210 M | 210 M | 210 M | 206 M | 206 M | 206 M | 206 M | 117 M | 117 M | 117 M | 117 M | 84 M | 84 M | 84 M | 84 M | 129 M | 129 M | 129 M | 129 M | 54.4 M | 54.4 M | 54.4 M | 54.4 M |
Total Shareholders Equity |
139 M | 128 M | 115 M | 105 M | 97.1 M | 92.1 M | 71.1 M | 48.5 M | 51 M | 53.4 M | 38.7 M | 30.4 M | 25.8 M | 21.6 M | 22.2 M | 19.7 M | 7.14 M | -2.45 M | -10.9 M | 29.5 M | 16.4 M | -5.95 M | -5.95 M | -5.95 M | -5.95 M | 17.5 M | 17.5 M | 17.5 M | 17.5 M | 34.3 M | 34.3 M | 34.3 M | 34.3 M | 53.3 M | 53.3 M | 53.3 M | 53.3 M | 210 M | 210 M | 210 M | 210 M | 206 M | 206 M | 206 M | 206 M | 117 M | 117 M | 117 M | 117 M | 84 M | 84 M | 84 M | 84 M | 129 M | 129 M | 129 M | 129 M | 54.4 M | 54.4 M | 54.4 M | 54.4 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Puma Biotechnology, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Schweiz
USA
China
Germany
Britain
France
Australia
Israel
